Mode
Text Size
Log in / Sign up

Community-Acquired Pneumonia

Part of Pneumonia

Subtypes of Community-Acquired Pneumonia

Community-acquired bacterial pneumonia 1 Mycoplasma pneumoniae CAP 1

19 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Community-Acquired Pneumonia

12 trials tracked for Community-Acquired Pneumonia: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 144 citations.

12Trials tracked
3Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 3 Phase 2 1 Phase 1 2 Other / NA 6
  1. Phase 3 Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia Completed · 144 cited
  2. Phase 3 Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia Completed · 111 cited
  3. Phase 3 Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia Completed
  4. Phase 2 A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP Completed
  5. Phase 1 Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia Completed
  6. Phase 1 Procalcitonin to Reduce Antibiotic Use in Pediatric Pneumonia Completed
Show 6 more trials
  1. N/A Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries Completed
  2. N/A Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Pneumonia and Pneumococcal Vaccine Completed
  3. N/A Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions Completed
  4. N/A Evaluation of the Treatment With Klacid®SR in Patients With Lower Respiratory Tract Infection Completed
  5. N/A Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin Completed
  6. N/A Improving Pneumococcal Vaccination Rates in an Ambulatory Pre-surgical Testing Setting Completed

Showing the 12 most-cited and recently-updated of 12 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Community-Acquired Pneumonia: what the trials found

Lefamulin has been evaluated in Phase 3 clinical trials for the treatment of community-acquired pneumonia (CAP) with sample sizes of 551 and 738 patients respectively [2, 3].

Omadacycline was evaluated in Phase 3 trials involving 670 participants. Results showed high rates of early clinical response at the ECR visit (89.6% vs 87.7% for active arms; 1.8% to 9.3% for placebo/comparator arms) and post-therapy evaluation (PTE) 4. In the clinically evaluable population, omadacycline demonstrated a clinical response rate of 94.1% and 95.9% at the PTE visit compared to 0% to 5.9% in comparison groups 4. Omadacycline was also evaluated in a Phase 1 trial involving 18 participants 7.

Recent results — preliminary, needs further review

  • MRSA Nasal Swab PCR was evaluated in a study of 277 patients, reporting vancomycin-free hours alive at 105.7 and 109.7 1.
  • A quasi-experimental intervention was conducted with a large cohort of 26,139 participants 8.

For the clinician treating this condition

  • Lefamulin is established in Phase 3 trials for community-acquired pneumonia [2, 3].
  • Omadacycline demonstrated high rates of both early clinical response and post-therapy clinical response in Phase 3 trials compared to control groups 4.

AI synthesis of 4 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Pneumonia

Related studies from across the Pneumonia family.

Autoantibody positivity and false-negative cytology can mask invasive mucinous adenocarcinoma in patients with IPAF
Allergy & Immunology Sys. Review
Autoantibody positivity and false-negative cytology can mask invasive mucinous adenocarcinoma in patients with IPAF Lung cancer can mimic autoimmune lung disease in some patients
This case report describes a 78-year-old female with invasive mucinous adenocarcinoma and interstitial pneumonia with autoimmune features. T…
A new case shows how a rare lung cancer can look like an autoimmune disease, making it hard for doctors to tell them apart.
Physical frailty tops risk factors for pneumonia after esophagectomy, meta-analysis finds
Geriatrics & Aging Meta-analysis
Physical frailty tops risk factors for pneumonia after esophagectomy, meta-analysis finds Physical frailty and muscle loss increase pneumonia risk after surgery
This meta-analysis of 60 cohort studies in esophageal cancer patients undergoing esophagectomy identified physical frailty as the highest-ra…
Patients with esophageal cancer face a higher risk of pneumonia after surgery if they show signs of physical frailty or muscle loss.
Short-course ceftriaxone reduces hospital stay and adverse events in children with pneumonia
Infectious Disease RCT
Short-course ceftriaxone reduces hospital stay and adverse events in children with pneumonia Shorter antibiotic courses may help children with pneumonia stay home
This randomized controlled trial of 200 children aged 1 to 14 years found that short-course ceftriaxone (5 to 7 days) resulted in shorter ho…
A new trial shows that a shorter course of ceftriaxone can reduce hospital stays and side effects for children with pneumonia.
Aerosolized liposomal amphotericin B provides strongest evidence for invasive pulmonary aspergillosis prophylaxis in high-risk patients
Gastroenterology Sys. Review
Aerosolized liposomal amphotericin B provides strongest evidence for invasive pulmonary aspergillosis prophylaxis in high-risk patients Aerosolized Amphotericin B Shows Promise for Lung Fungal Infections
This mini review synthesizes clinical experience regarding aerosolized antifungal therapies for various pulmonary fungal infections. It conc…
Aerosolized liposomal amphotericin B shows promise for preventing specific lung fungal infections in high-risk and immunocompromised patient…
mNGS achieves 85.83% pathogen detection rate in children with severe pneumonia compared to 49.97% for conventional methods
Pediatrics Sys. Review
mNGS achieves 85.83% pathogen detection rate in children with severe pneumonia compared to 49.97% for conventional methods New Genetic Test Finds More Pneumonia Germs in Kids
This systematic review evaluates metagenomic next-generation sequencing (mNGS) for identifying pathogens in children with severe pneumonia. …
A new genetic test detects pneumonia-causing germs in kids more often than standard methods, which could lead to better treatment.
Inhaled antibiotics may improve lung function and microbiological eradication in cystic fibrosis and bronchiectasis
Infectious Disease Meta-analysis
Inhaled antibiotics may improve lung function and microbiological eradication in cystic fibrosis and bronchiectasis Inhaled Antibiotics May Improve Lung Health in Chronic Lung Conditions
This meta-analysis evaluated the efficacy of inhaled antibiotics for patients with cystic fibrosis, non-cystic fibrosis bronchiectasis, and …
Inhaled antibiotics may improve lung function and clear infections for people with cystic fibrosis and other chronic lung conditions.
Antibiotic exposure disrupts gut microbiota in 58% to 94% of critically ill children
Infectious Disease Sys. Review
Antibiotic exposure disrupts gut microbiota in 58% to 94% of critically ill children Antibiotics and gut health in critically ill children
This narrative review examines antibiotic exposure in critically ill children in the PICU, reporting that 58% to 94% receive antibiotics, wh…
Common antibiotics used in intensive care can disrupt a child's gut health, increasing the risk of serious infections like pneumonia.
iNKT cell activators show promise in preclinical models for stroke-associated pneumonia immunomodulation
Pulmonology & Critical Care Meta-analysis
iNKT cell activators show promise in preclinical models for stroke-associated pneumonia immunomodulation New immune treatments show promise for stroke and pneumonia
This systematic review of 38 preclinical studies examines the immunopathology of stroke-associated pneumonia (SAP) and the role of immunomod…
Researchers identify how stroke triggers immune failure and find a promising new way to protect the lungs from pneumonia infections.
IL-6 overexpression linked to alveolar damage in severe pneumonia on ventilation
Primary Care & Family Medicine Sys. Review
IL-6 overexpression linked to alveolar damage in severe pneumonia on ventilation IL-6 Levels Linked to Lung Damage in Severe Pneumonia
This narrative review synthesizes basic and clinical evidence on IL-6 in mechanically ventilated patients with severe pneumonia. It finds th…
High levels of a protein called IL-6 may be linked to increased lung damage and inflammation in patients with severe pneumonia.
Impact of Systemic Prophylactic Antibacterials on Ventilator Associated Pneumonia in ICU Patients
Infectious Disease Meta-analysis
Impact of Systemic Prophylactic Antibacterials on Ventilator Associated Pneumonia in ICU Patients Antibacterials may lower pneumonia rates in patients on ventilators
Meta-analysis data suggests systemic prophylactic antibacterials significantly reduce the incidence of ventilator-associated pneumonia in IC…
A large review suggests that using certain medications can help prevent lung infections in patients requiring breathing machines in the ICU.
Nursing Care Improves Pediatric Pneumonia Outcomes
Pediatrics Meta-analysis
Nursing Care Improves Pediatric Pneumonia Outcomes Nursing care boosts satisfaction, cuts pneumonia complications in kids
Meta-analysis of 166,859 pediatric pneumonia cases shows nursing interventions boost satisfaction and cut complications.
Structured nursing care for children with pneumonia improves satisfaction and reduces complications, a large meta-analysis finds.
Precision synbiotic reduces URTI incidence from 85.4% to 55.4% in toddlers
Nutrition & Obesity Medicine RCT
Precision synbiotic reduces URTI incidence from 85.4% to 55.4% in toddlers New synbiotic formula may cut common toddler infections and eczema
This multicenter randomized controlled trial of 390 healthy toddlers aged 1-3 years found that a precision synbiotic significantly reduced u…
A new combination of a specific sugar and healthy bacteria could significantly reduce respiratory infections, diarrhea, and skin issues in t…

Questions about Community-Acquired Pneumonia

What are the risks of co-infection in children with HMPV and severe community-acquired pneumonia?

Co-infection, especially with Mycoplasma pneumoniae, is a significant risk factor for severe CAP in children with HMPV, with studies showing higher rates of co-infection in severe cases.

Full answer →
Are children with severe community-acquired pneumonia more likely to have Mycoplasma pneumoniae?

Yes, children with severe community-acquired pneumonia are more likely to have Mycoplasma pneumoniae, with studies showing higher detection rates in severe cases.

Full answer →
Can machine learning predict mortality better than APACHE-II for severe community-acquired pneumonia?

Yes, machine learning models, particularly GBDT and XGBoost, have outperformed APACHE-II in predicting mortality for severe community-acquired pneumonia with respiratory failure.

Full answer →
What is the severe community-acquired pneumonia rate for children with HMPV?

In a recent study of hospitalized children with HMPV, 28.0% had severe community-acquired pneumonia (CAP).

Full answer →
How does the severity of community-acquired pneumonia affect the detection of Mycoplasma pneumoniae in children?

Severe community-acquired pneumonia in children is associated with higher detection rates of Mycoplasma pneumoniae compared to non-severe cases, likely due to higher bacterial load and immune response.

Full answer →
Does amoxicillin work just as well as other antibiotics for community-acquired pneumonia?

Current evidence suggests amoxicillin is generally as effective as other antibiotics for community-acquired pneumonia, but the choice depends on local resistance patterns and patient factors.

Full answer →
See all 6 questions about Community-Acquired Pneumonia →